Background Matrix metalloproteinase-9 (MMP-9) contributes to chronic lymphocytic leukemia (CLL) pathology by regulating cell migration and preventing spontaneous apoptosis. It is not known if MMP-9 is involved in CLL cell response to chemotherapy and we address this in the present study, using arsenic trioxide (ATO) and fludarabine as examples of cytotoxic drugs. Methods We used primary cells from the peripheral blood of CLL patients and MEC-1 cells stably transfected with an empty vector or a vector containing MMP-9. The effect of ATO and fludarabine was determined by flow cytometry and by the MTT assay. Expression of mRNA was measured by RT-PCR and qPCR. Secreted and cell-bound MMP-9 was analyzed by gelatin zymography and flow cytometry, respectively. Protein expression was analyzed by Western blotting and immunoprecipitation. Statistical analyses were performed using the two-tailed Student's t-test. Results In response to ATO or fludarabine, CLL cells transcriptionally upregulated MMP-9, preceding the onset of apoptosis. Upregulated MMP-9 primarily localized to the membrane of early apoptotic cells and blocking apoptosis with Z-VAD prevented MMP-9 upregulation, thus linking MMP-9 to the apoptotic process. Culturing CLL cells on MMP-9 or stromal cells induced drug resistance, which was overcome by anti-MMP-9 antibodies. Accordingly, MMP-9-MEC-1 transfectants showed higher viability upon drug treatment than Mock-MEC-1 cells, and this effect was blocked by silencing MMP-9 with specific siRNAs. Following drug exposure, expression of anti-apoptotic proteins (Mcl-1, Bcl-xL, Bcl-2) and the Mcl-1/Bim, Mcl-1/Noxa, Bcl-2/Bax ratios were higher in MMP-9-cells than in Mock-cells. Similar results were obtained upon culturing primary CLL cells on MMP-9. Conclusions Our study describes for the first time that MMP-9 induces drug resistance by modulating proteins of the Bcl-2 family and upregulating the corresponding anti-apoptotic/pro-apoptotic ratios. This is a novel role for MMP-9 contributing to CLL progression. Targeting MMP-9 in combined therapies may thus improve CLL response to treatment.
References
[1]
Zenz T, Mertens D, Küppers R, D？hner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10: 37–50. doi: 10.1038/nrc2764
[2]
Gaidano G, Foa, Dalla-Favera R (2012) Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 122: 3432–3438. doi: 10.1172/jci64101
[3]
Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6: 405–418. doi: 10.1038/nrclinonc.2009.72
[4]
Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88: 803–816. doi: 10.1002/ajh.23491
[5]
Stephens DM, Byrd JC (2013) Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. Hematol Oncol Clin North Am 27: 303–327. doi: 10.1016/j.hoc.2012.12.003
[6]
Wang Z-Y, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505–2515. doi: 10.1182/blood-2007-07-102798
[7]
Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z (2012) How to manage acute promyelocytic leukemia. Leukemia 26: 1743–1751. doi: 10.1038/leu.2012.57
[8]
Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, et al. (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86: 541–552. doi: 10.1007/s00109-008-0314-6
[9]
Redondo-Mu？oz J, Escobar-Díaz E, Hernández del Cerro M, Pandiella A, Terol MJ, et al. (2010) Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 16: 4382–4391. doi: 10.1158/1078-0432.ccr-10-0072
[10]
Burger JA (2012) Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24: 643–649. doi: 10.1097/cco.0b013e3283589950
[11]
Ramsay AD, Rodriguez-Justo M (2013) Chronic lymphocytic leukemia-the role of the microenvironment pathogenesis and therapy. Br J Haematol 162: 15–24. doi: 10.1111/bjh.12344
[12]
Vandooren J, Van den Steen PE, Opdenakker G (2013) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48: 222–272. doi: 10.3109/10409238.2013.770819
[13]
Bauvois B, Dumont J, Mathiot C, Kolb JP (2002) Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 16: 791–798. doi: 10.1038/sj.leu.2402472
[14]
Redondo-Mu？oz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, et al. (2006) MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108: 3143–3151. doi: 10.1182/blood-2006-03-007294
[15]
Redondo-Mu？oz J, Terol MJ, García-Marco JA, García-Pardo A (2008) Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 111: 383–386. doi: 10.1182/blood-2007-08-107300
[16]
Redondo-Mu？oz J, Ugarte-Berzal E, García-Marco JA, Hernández del Cerro M, Van den Steen PE, et al. (2008) α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169–178. doi: 10.1182/blood-2007-08-109249
[17]
Redondo-Mu？oz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández del Cerro M, et al. (2010) Matrix Metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through Its hemopexin domain. Cancer Cell 17: 160–172. doi: 10.1016/j.ccr.2009.12.044
[18]
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2: 161–174. doi: 10.1038/nrc745
[19]
Mannello F, Luchetti E, Falcieri E, Papa S (2005) Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10: 19–24. doi: 10.1007/s10495-005-6058-7
[20]
Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, Van den Steen P, Opdenakker G, et al. (2014) Overexpression of pro-gelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. J Leuk Biol in press. doi: 10.1189/jlb.0913521
[21]
Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P (1999) MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23: 127–136. doi: 10.1016/s0145-2126(98)00154-4
[22]
Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H (1992) Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285: 603–611.
[23]
Shooshtari P, Fortuno ES, Blimkie D, Yu M, Gupta A, et al. (2010) Correlation Analysis of Intracellular and Secreted Cytokines via the Generalized Integrated Mean Fluorescence Intensity (GiMFI). Cytometry A 77: 873–880. doi: 10.1002/cyto.a.20943
[24]
Jayo A, Conde I, Lastres P, Martínez C, Rivera J, et al. (2010) L718P mutation in the membrane-proximal cytoplasmic tail of β3 promotes abnormal αIIβ3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica 95: 1158–1166. doi: 10.3324/haematol.2009.018572
[25]
Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37: 375–536. doi: 10.1080/10409230290771546
[26]
Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 24: 71–81. doi: 10.1016/j.semcancer.2013.08.011
[27]
Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49–63. doi: 10.1038/nrm3722
[28]
Gandhi V, Balakrishnan K, Chen LS (2008) Mcl-1: the 1 in CLL. Blood 112: 3538–3540. doi: 10.1182/blood-2008-07-170241
[29]
Nyormoi O, Mills L, Bar-Eli M (2003) An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10: 558–569. doi: 10.1038/sj.cdd.4401209
[30]
Meyer E, Vollmer JY, Boyer R, Stamenkovic (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 65: 4261–4272. doi: 10.1158/0008-5472.can-04-2908
[31]
Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK (2010) Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther 9: 2605–2617. doi: 10.1158/1535-7163.mct-10-0245
[32]
Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R (2011) Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Research 71: 6986–6996. doi: 10.1158/0008-5472.can-11-0629
[33]
Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, et al. (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5: 3113–3121. doi: 10.1158/1535-7163.mct-06-0228
[34]
Balakrishnan K, Burger JA, Wierda WG, Gandhi V (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance. Blood 113: 149–153. doi: 10.1182/blood-2008-02-138560
[35]
Buchner M, Baer C, Prinz G, Dierks C, Burger M, et al. (2010) Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115: 4497–4506. doi: 10.1182/blood-2009-07-233692
[36]
Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M (2008) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112: 2450–2460. doi: 10.1182/blood-2007-10-114348
[37]
Wang R, Xia L, Gabrilove J, Waxman S, Jing Y (2013) Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 27: 315–324. doi: 10.1038/leu.2012.180
[38]
Baysan A (2007) Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 30: 313–318.
[39]
Morales AA, Gutman D, Boise LH (2008) BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111: 5152–5162. doi: 10.1182/blood-2007-10-116889
[40]
Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, et al. (2013) BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis 4: e628. doi: 10.1038/cddis.2013.155
[41]
de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, et al. (2002) Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71: 495–502.
